These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17668794)

  • 41. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs.
    Cahn LJ
    Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372
    [No Abstract]   [Full Text] [Related]  

  • 42. [Therapy of hypertension. Cost conscious prevention of complications].
    Kolloch RE
    MMW Fortschr Med; 2003 Nov; 145(47):64. PubMed ID: 14725042
    [No Abstract]   [Full Text] [Related]  

  • 43. [Free trade agreements make the drugs more expensive].
    Jeppsson A
    Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499
    [No Abstract]   [Full Text] [Related]  

  • 44. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generic medicines in the Malaysian health care system: Opportunities and challenges.
    Wong ZY; Alrasheedy AA; Hassali MA; Saleem F
    Res Social Adm Pharm; 2016; 12(5):807-10. PubMed ID: 27157864
    [No Abstract]   [Full Text] [Related]  

  • 46. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Grice S
    N Z Bioeth J; 2003 Oct; 4(3):22-4. PubMed ID: 15597479
    [No Abstract]   [Full Text] [Related]  

  • 47. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Millions of old cost burdens. The time bomb of overdue drug budgets].
    Bossmann A
    Chirurg; 1998 Apr; 69(4):suppl 116-8. PubMed ID: 9612626
    [No Abstract]   [Full Text] [Related]  

  • 49. Legal tactics to delay launch of generic drugs cost Europe euro3bn, report says.
    Jack A
    BMJ; 2008 Dec; 337():a2817. PubMed ID: 19047187
    [No Abstract]   [Full Text] [Related]  

  • 50. The scandal of generic drug pricing: drug regulation policies need review.
    Meeran K; Choudhury SM; Wass J
    BMJ; 2017 Feb; 356():j947. PubMed ID: 28232321
    [No Abstract]   [Full Text] [Related]  

  • 51. [Lean years for patients].
    Klose G; Anlauf M
    MMW Fortschr Med; 2004 Dec; 146(51-52):16. PubMed ID: 15675237
    [No Abstract]   [Full Text] [Related]  

  • 52. Angst about exclusivity: The potential cost of incentivizing makers of generic drugs.
    Chakradhar S; Khamsi R
    Nat Med; 2017 Oct; 23(10):1114-1116. PubMed ID: 28985215
    [No Abstract]   [Full Text] [Related]  

  • 53. [Assessment of novel antidiabetic drugs in Germany. Do innovations still have a chance?].
    Gallwitz B
    MMW Fortschr Med; 2014 Jul; 156(13):57-60. PubMed ID: 25318228
    [No Abstract]   [Full Text] [Related]  

  • 54. Brand-name versus generic.
    Copeland KR; Boccuzzi SJ
    Health Aff (Millwood); 2007; 26(4):1198-9; author reply 1199. PubMed ID: 17630468
    [No Abstract]   [Full Text] [Related]  

  • 55. [HIV infection and AIDS from the health policy viewpoint. Savings and therapy superiority maintained - a contradiction in HIV therapy?].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():62-3. PubMed ID: 25026863
    [No Abstract]   [Full Text] [Related]  

  • 56. Economics of biological therapies.
    Kelly CJ; Mir FA
    BMJ; 2009 Aug; 339():b3276. PubMed ID: 19700510
    [No Abstract]   [Full Text] [Related]  

  • 57. [Prescription of generic drugs to privately insured persons].
    Wild F
    Versicherungsmedizin; 2012 Dec; 64(4):190-2. PubMed ID: 23236709
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Woolner D
    N Z Bioeth J; 2003 Oct; 4(3):22, 25-6. PubMed ID: 15597481
    [No Abstract]   [Full Text] [Related]  

  • 59. [Tablet splitting: do discount contracts influence prescribing quality?].
    Quinzler R; Bertsche T; Szecsenyi J; Haefeli WE
    Med Klin (Munich); 2008 Aug; 103(8):569-74. PubMed ID: 18807231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The potential of selective contracts in Germany--pro].
    Martinsohn-Schittkowski W; Sühlfleisch-Thurau U; Tolzin CJ
    Psychiatr Prax; 2012 Nov; 39(8):367-8. PubMed ID: 23138326
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.